Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Previously Treated With Trastuzumab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 0 results

Not applicableUnknownNCT01424865
What this trial is testing

Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial

Who this might be right for
Breast Cancer
NSABP Foundation Inc 1,874
Testing effectiveness (Phase 2)Study completedNCT04539938
What this trial is testing

Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 70
Early research (Phase 1)Ended earlyNCT03062007
What this trial is testing

Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab

Who this might be right for
Metastatic Breast Cancer
Biointegrator LLC 6
Not applicableActive Not RecruitingNCT07810634
What this trial is testing

Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab

Who this might be right for
Breast Cancer
Beijing 302 Hospital 200
Testing effectiveness (Phase 2)Study completedNCT00301899
What this trial is testing

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Who this might be right for
Breast Cancer
National Institutes of Health Clinical Center (CC) 37
Large-scale testing (Phase 3)Looking for participantsNCT06435429
What this trial is testing

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Who this might be right for
Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals 550
Early research (Phase 1)Study completedNCT01434303
What this trial is testing

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Who this might be right for
HER2/Neu PositiveInvasive Breast CarcinomaRecurrent Breast Carcinoma+1 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Study completedNCT00407888
What this trial is testing

Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-positive Breast CancerStage IA Breast Cancer+6 more
University of Washington 60
Not applicableStudy completedNCT02056080
What this trial is testing

Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib

Who this might be right for
Breast Neoplasm
MedSIR 111
Large-scale testing (Phase 3)Active Not RecruitingNCT05063786
What this trial is testing

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

Who this might be right for
Advanced Breast Cancer
Spanish Breast Cancer Research Group 27
Large-scale testing (Phase 3)Study completedNCT04499924
What this trial is testing

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
Seagen Inc. 17
Large-scale testing (Phase 3)Active Not RecruitingNCT04739761
What this trial is testing

T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 506
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07726342
What this trial is testing

SMP-656 for HER2-Positive Advanced Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd. 60
Testing effectiveness (Phase 2)Study completedNCT02448420
What this trial is testing

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 73
Testing effectiveness (Phase 2)Looking for participantsNCT06750484
What this trial is testing

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Who this might be right for
Breast Cancer Metastatic
Yale University 40
Large-scale testing (Phase 3)Ended earlyNCT01450696
What this trial is testing

Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 296
Not applicableStudy completedNCT05458401
What this trial is testing

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Who this might be right for
HER2-positive Breast Cancer
Daiichi Sankyo 256